noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Kirkland & Ellis LLP

Private Equity/M&A Partner Adam Prince Joins Kirkland & Ellis
Oakland University

Natalie Ishioka named Student of the Year by the Great Lakes Affiliate[...]
ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)

Healthcare

Pappas Capital LLC

05/09/2014 | Press release | Archived content

Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 ...

News | 05. 09. 2014

Lumena Pharmaceuticals

CAMEO Phase 2 Clinical Trial of LUM001 Now Enrolling Adults with Primary Sclerosing Cholangitis

SAN DIEGO - May 9, 2014 - Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced the dosing of the first patient in the INDIGO Phase 2 clinical trial of its lead drug candidate, LUM001, in children with progressive familial intrahepatic cholestasis (PFIC). Additionally, the CAMEO Phase 2 clinical trial of LUM001 in adults with primary sclerosing cholangitis (PSC) is open for enrollment.

Pappas Capital LLC published this content on May 09, 2014, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format